CyberKnife Ultra-hypofractionated SBRT for Localized PROStatE cancEr With Dose-escalation to the Dominant Intraprostatic Lesion: is the Juice Worth the Squeeze? The PRO-SPEED Trial
This is a prospective observational study. The study will proceed with the enrollment of 60 patients in 2 years. he aim of the present study is to evaluate effectiveness of ultra-hypofractionated (UH) CyberKnife Stereotactic Body Radiation Therapy treatment on the whole prostate gland plus Simultaneous integrated boost (SIB) to the dominant intraprostatic lesions (DIL(s) in intermediate-unfavourable to high-risk Prostate Cancer (PCa) patients.
• Age \> 18 and \< 80 years
• Histologically confirmed adenocarcinoma of the prostate
• Low, Intermediate and high-risk category according to NCCN version 02.2021
• Clinically node negative and no distant metastasis
• Eastern Cooperative Oncology Group (ECOG) Performance Status \<2
• Good urinary flow (peak flow \>10 mL/s) or IPSS \< 15
• Prostate volume \< 100 cc
• Available mpMRI of the prostate
• Less than 3 DILs at mpMRI (if \>2 DILs, only DILs with higher Prostate Imaging - Reporting and Data System (PIRADS) will be included and only PI-RADS \>2)
• Written informed consent for treatment and research purpose